This practice quit study will take place in two different locations—New Haven, CT and Kiev, Ukraine. Participants for the New Haven Trial will be recruited from general public and from Yale’s Tobacco Treatment Service from April 2021 to December 31, 2021. Participants for the Kiev trial will also be recruited from the general public using ads on socia media and pamphleting at local markets during the same period.
The study procedures for the two trial will be identical except that (1) the New Haven trial’s intake and CO testing will be done remotely while the Kiev location will have in-person meetings with subject participations and (2) the specific attendance and abstinence rewards described in detail below will be denominated in local currency.
We will include individuals who are adults and smoke more than 3 cigaretters per week and exclude individuals that have unstable psychiatric/medical conditions (see below for details on the exclusion criteria). At an initial intake meeting, research staff would inform patients about the study. Those who expressed interest would complete informed consent, baseline assessments, and a breath carbon monoxide (CO) reading (Bedfont Micro+ Smokerlyzer) to verify smoking status (i.e., defined as >4ppm).
At this intake appointment, patients would be randomized into the two arms, with blocking stratification by Fagerstrom scores. As suggested in the literature, participants would be placed in high nicotine dependence group if Fagerstrom score was greater than 5 (and in low dependence group if their score was below this cutoff) (Schnoll et al 2013). Allocation would be concealed, and each participant would be assigned the next sequential number by a research staff member who was blinded to the allocation sequence using Redcap.
Remote CO testing will be done using breathalyzers that connect with the participants’ phone. An administrator will observe the participant taking each CO test via Zoom.